文献速递肾癌与肾肿瘤

m6A去甲基化酶ALKBH5与FTO在透明细胞肾细胞癌中的预后生物标志物价值

The N6 -methyladenosine (m6 A) erasers alkylation repair homologue 5 (ALKBH5) and fat mass and obesity-associated protein (FTO) are prognostic biomarkers in patients with clear cell renal carcinoma.
PubMed 文献 · BJU Int · 2020-02-17

本研究基于Cologne-Bonn生物样本库组织芯片和qRT-PCR,检测ALKBH5与FTO在透明细胞肾细胞癌及其他肾肿瘤中的表达。结果发现ccRCC中ALKBH5 mRNA及ALKBH5、FTO蛋白表达显著下调,且ALKBH5与FTO mRNA低表达与肾切除术后总生存期和肿瘤特异性生存期缩短相关,提示二者可作为ccRCC预后生物标志物。

要点

  • ccRCC中ALKBH5 mRNA及ALKBH5、FTO蛋白表达显著下调。
  • ALKBH5与FTO mRNA低表达与肾切除术后总生存期和肿瘤特异性生存期缩短相关。
  • ALKBH5与FTO或可作为ccRCC预后生物标志物。

核心结论

  • m6A去甲基化酶ALKBH5和FTO在ccRCC中表达失调,或可作为预后生物标志物。

研究设计与样本

  • 组织样本来自Cologne-Bonn综合肿瘤中心生物样本库,采用qRT-PCR检测ALKBH5与FTO基因表达。
  • 利用组织芯片在ccRCC、乳头状RCC、嫌色细胞RCC、肉瘤样RCC、嗜酸细胞瘤及良性肾组织中进一步研究ALKBH5与FTO表达。

主要发现

  • 与正常组织及多数其他 studied 肿瘤实体相比,ccRCC中ALKBH5 mRNA以及ALKBH5和FTO蛋白表达显著下调。
  • ALKBH5和FTO mRNA水平降低与肾切除术后总生存期和肿瘤特异性生存期缩短相关。

临床怎么用

  • ALKBH5与FTO表达水平可能有助于ccRCC患者肾切除术后的预后评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To comprehensively investigate the role of the N6 -methyladenosine (m6 A) erasers ALKBH5 and FTO in clear cell renal cell carcinoma (ccRCC), other RCC subtypes, and oncocytoma with respect to prognostic value and biomarker potential. PATIENTS AND METHODS: The collection of tissue samples was performed within the framework of the Biobank at the Centre for Integrated Oncology Cologne-Bonn. The gene expressions of alkylation repair homologue 5 (ALKBH5) and fat mass and obesity-associated protein (FTO) were determined using quantitative real-time polymerase chain reaction. ALKBH5 and FTO expressions were further investigated in ccRCC, papillary RCC, chromophobe RCC, sarcomatoid RCC, oncocytoma, and benign renal tissue using tissue microarrays. RESULTS: ALKBH5 mRNA, as well as ALKBH5 and FTO protein expressions, was significantly downregulated in ccRCC compared to normal tissue and most of the other studied tumour entities. Decreased mRNA levels of ALKBH5 and FTO correlated with a shortened overall and cancer-specific survival following nephrectomy. CONCLUSIONS: Taken together, our present data indicate that the m6 A-demethylases ALKBH5 and FTO are dysregulated in ccRCC and could be used as prognostic biomarkers.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Strick A, von Hagen F, Gundert L, et al. The N6 -methyladenosine (m6 A) erasers alkylation repair homologue 5 (ALKBH5) and fat mass and obesity-associated protein (FTO) are prognostic biomarkers in patients with clear cell renal carcinoma. BJU Int. 2020. PMID: 31985880. doi:10.1111/bju.15019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。